AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33087345
Drug: nTreg infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nTreg infusion (0.5, 1.0, or 2.5-3.0×10^6 cells)
Trial: 33087345
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (standard dual or triple drug immunosuppression)
Trial: 33087548
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT lung cancer screening (LDCT)
Trial: 33088573
Drug: PBMT-sMF (photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT-sMF (photobiomodulation therapy combined with static magnetic field)
Trial: 33089005
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release transdermal nicotine
Trial: 33089304
Drug: CDR132L (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDR132L (monthly intravenous treatments over 3 or 5 months)
Trial: 33089593
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of treatment for bipolar disorder
Trial: 33090333
Drug: Cetuximab (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (loading dose followed by weekly infusions of 250 mg/m2)
Trial: 33090368
Drug: Pregabalin treatment
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin treatment in FM patients.
Trial: 33091124
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood (CB)-derived adoptive cell therapy after salvage chemotherapy
Trial: 33091124
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood (CB)-derived adoptive cell therapy
Trial: 39252018
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder (MOUD)
Trial: 33091842
Drug: Safer opioid
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safer opioid analgesic prescribing
Trial: 33092403
Drug: Ibrutinib treatment
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib treatment for 4 weeks
Trial: 33092403
Drug: Acalabrutinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib treatment for 4 weeks
Trial: 33092403
Drug: Kinase inhibitors
RxNorm normalized name: PROTEIN KINASE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinase inhibitors blocking Csk
Trial: 33092438
Drug: hs-CRP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP level <1.0 mg/L
Trial: 33092646
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss treatment including Very Low Energy Diet (VLED)
Trial: 34966107
Drug: Imlifidase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imlifidase treatment
Trial: 33093900
Drug: Intravitreal administration
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal administration of bevacizumab (Lumiere)
Trial: 33094474
Drug: Venetoclax monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax monotherapy (400 mg/day)
Trial: 33094474
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus rituximab (400 mg/day)
Trial: 33095117
Drug: Fludarabine-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine-based therapies
Trial: 33095117
Drug: C/CHOP-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/CHOP-based therapies
Trial: 33095117
Drug: Chlorambucil-based therapy
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil-based therapy
Trial: 33095117
Drug: Novel therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapies (kinase inhibitors)
Trial: 33095287
Drug: Crizotinib at
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib at 215 mg/m² in combination with cyclophosphamide and topotecan
Trial: 33095287
Drug: Crizotinib at
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib at 165 mg/m² and 280 mg/m²
Trial: 33095411
Drug: XC8 2
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XC8 2 mg
Trial: 33095411
Drug: XC8 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 10 mg
Trial: 33095411
Drug: XC8 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 100 mg
Trial: 33095874
Drug: Unlabeled daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unlabeled daratumumab (0 mg, 10 mg, 45 mg, 95 mg)
Trial: 37556023
Drug: Lurbinectedin 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m²
Trial: 33096476
Drug: Chemo-radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-radiation treatment
Trial: 33097612
Drug: Emactuzumab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab (500 to 1000 mg) and Selicrelumab (2 to 16 mg) administered intravenously every 3 weeks
Trial: 33097687
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin (3.4 mg/kg, every 3 weeks)
Trial: 33098195
Drug: Neoadjuvant carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant carboplatin (AUC 6) every 28 days for four cycles plus nab-paclitaxel (100 mg/m2)
Trial: 33099491
Drug: Isotoxic hypofractionated
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotoxic hypofractionated concurrent chemoradiotherapy with docetaxel plus lobaplatin
Trial: 33099678
Drug: arfolitixorin (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arfolitixorin (at four dose levels)
Trial: 33099742
Drug: Lobeglitazone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone (0.5 mg for 24 weeks)
Trial: 33099742
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg for 24 weeks)
Trial: 33100036
Drug: LVAD support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVAD support combined with standardized pharmacological therapy and cardiac function monitoring protocol
Trial: 33101027
Drug: Patch containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch containing Allium cepa and allantoin
Trial: 33101027
Drug: Patch containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch containing Allium cepa and allantoin (Group B)
Trial: 33101079
Drug: Probiotics (De
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (De Simone Formulation)
Trial: 33101409
Drug: SHBG <26.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHBG <26.75 mmol/L
Trial: 33102224
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy and systemic therapy, specific details not available.
Trial: 33102510
Drug: Fermented whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented whey concentrate (FWC) drink rich in L-(+)-Lactic acid, consumed daily
Trial: 33103032
Drug: 150-mg once-monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg once-monthly risedronate
Trial: 33104796
Drug: Ruxolitinib 25
RxNorm normalized name: ruxolitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 25 mg twice daily for induction, followed by 10 mg twice daily for subsequent cycles, combined with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle.
Trial: 33104796
Drug: Ruxolitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib and decitabine combination treatment.
Trial: 33105385
Drug: Sildenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil treatment for 4 weeks
Trial: 33106665
Drug: Precision medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision medicine treatment based on prospective genomic profiling
Trial: 33107983
Drug: Crenigacestat (LY3039478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (LY3039478) at 50 mg, 75 mg, 100 mg, and 125 mg orally 3 times per week plus dexamethasone at 24 mg twice daily on days 1 to 5 every other week in a 28-day cycle.
Trial: 33108270
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) treatment with ≥6-hour use
Trial: 33108270
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) treatment with ≥4-hour use
Trial: 33108543
Drug: Elagolix 200
RxNorm normalized name: elagolix 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 200 mg twice daily
Trial: 33109505
Drug: Juice intake
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice intake (8 oz daily)
Trial: 33109505
Drug: Water/Sugar-Free Beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water/Sugar-Free Beverage (SFB) intake (8 oz daily)
Trial: 33109505
Drug: Sugar-Sweetened Beverages
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-Sweetened Beverages (SSB) intake (8 oz daily)
Trial: 33109505
Drug: Toothbrushing (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothbrushing (additional daily event)
Trial: 33109627
Drug: Ribociclib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib and letrozole (400 mg of ribociclib and 2.5 mg of letrozole daily)
Trial: 33110622
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cholecalciferol (1600 IU/day for < 1 year, 2400 IU/day for > 1 year)
Trial: 33112242
Drug: ePRO follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePRO follow-up using a weekly questionnaire evaluating symptoms and an urgency algorithm for alerts.
Trial: 33113214
Drug: Combined CCNU/TMZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CCNU/TMZ therapy
Trial: 33114652
Drug: Atu027 (0.235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atu027 (0.235 mg/kg twice weekly) + Gemcitabine
Trial: 33114652
Drug: Atu027 (0.235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atu027 (0.235 mg/kg once weekly) + Gemcitabine
Trial: 33115374
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg amiselimod
Trial: 33115374
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg amiselimod
Trial: 33115374
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg and 0.4 mg amiselimod
Trial: 33117015
Drug: Interactive Music
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Music Therapy (IMT)
Trial: 33117256
Drug: Combined IAMZS
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined IAMZS (20 min) and medication
Trial: 33117256
Drug: Sole medication
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole medication
Trial: 33117454
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily for one week
Trial: 33117895
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy combined with music therapy (10 therapy sessions and related homework)
Trial: 33117961
Drug: Transcutaneous tibial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous tibial nerve stimulation; details on dosage and duration not available.
Trial: 33119478
Drug: Intraperitoneal radioimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal radioimmunotherapy (RIT) with anti-B7H3 murine monoclonal antibody
Trial: 33121236
Drug: Danicopan monotherapy
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan monotherapy (100-200 mg thrice daily)
Trial: 33122543
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine infusions (median duration 20.5 hours) with paracetamol 4 times daily and rescue morphine for unacceptable pain (numerical rating scale ≥4)
Trial: 33122898
Drug: Any Triple
RxNorm normalized name: WITCH HAZEL 500 mg in 1 g / LIDOCAINE 50 mg in 1 g / PHENYLEPHRINE HYDROCHLORIDE 2.5 mg in 1 g TOPICAL CLOTH [The Pharma C Company Triple Action Hemorrhoidal Pads]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any Triple Combination Therapy
Trial: 33123048
Drug: Reduced Environmental
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Environmental Stimulation Therapy (REST)
Trial: 33123384
Drug: Hepatocyte matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatocyte matrix implant
Trial: 33124006
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg once daily
Trial: 33124006
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg once daily
Trial: 33124006
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drugs with known impact on lipid profile (protease inhibitors, efavirenz, cobicistat)
Trial: 33125295
Drug: Simplified algorithm
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simplified algorithm for prevention and early treatment of bleeding, differentiation syndrome, and infection; education of oncologists about early deaths in APL; frequent communication between expert and treating physician in the first 2 weeks.
Trial: 33125309
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg and ipilimumab 3 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.
Trial: 33125520
Drug: Senolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senolytic treatment targeting senescent cells
Trial: 33125520
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of SA-β-gal in subcutaneous adipose tissue
Trial: 33125909
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy (taselisib, palbociclib, AZD4547, rilotumumab plus erlotinib, talazoparib, telisotuzumab vedotin)
Trial: 33125909
Drug: Anti-PD-1 or
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 or anti-PD-L1 therapy (durvalumab, nivolumab plus ipilimumab)
Trial: 33125909
Drug: Docetaxel (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (second line therapy)
Trial: 33125909
Drug: Anti-PD-1 or
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 or anti-PD-L1-containing therapies
Trial: 33126339
Drug: T-DM1 at
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 at 3.6 mg/kg every 3 weeks
Trial: 33127750
Drug: Reformulated T3
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated T3 (2.73 µg T3 in 300 µl for 5 consecutive days)
Trial: 33128080
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES)
Trial: 33128299
Drug: Pamiparib 20
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 20 mg BID
Trial: 33128299
Drug: Pamiparib 40
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 40 mg BID
Trial: 33128299
Drug: Pamiparib 60
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 60 mg BID
Trial: 33128347
Drug: Avacopan 10
RxNorm normalized name: avacopan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avacopan 10 mg plus standard-of-care (SOC)
Trial: 33128347
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg plus standard-of-care (SOC)
Trial: 33128347
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg plus SOC
Trial: 33128347
Drug: Avacopan 10
RxNorm normalized name: avacopan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avacopan 10 mg plus SOC
Trial: 33128873
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg CH5126766 three times per week
Trial: 33128873
Drug: 3.2 mg
RxNorm normalized name: menthol 3.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg CH5126766 three times per week
Trial: 33128873
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg CH5126766 twice per week
Trial: 33128873
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg CH5126766 (various schedules)
Trial: 33128903
Drug: Fostemsavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (600 mg twice a day) in combination with failing regimen for 8 days, followed by fostemsavir plus optimised background therapy
Trial: 33128903
Drug: Fostemsavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (600 mg twice a day) plus optimised background therapy from day 1
Trial: 33130556
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to treatment guidelines
Trial: 33131027
Drug: Zolpidem (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (5 or 10 mg) daily for 2 weeks
Trial: 33131912
Drug: Ceftriaxone (empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (empirical antibiotic)
Trial: 33131912
Drug: In vitro-active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro-active antibiotics
Trial: 33131933
Drug: Hantavax® (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months)
Trial: 33131933
Drug: Hantavax® (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hantavax® (booster dose at 13 months)
Trial: 33131933
Drug: Hantavax® (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hantavax® (three primary doses)
Trial: 33131933
Drug: Hantavax® (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hantavax® (booster doses)
Trial: 33132297
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Men-ACWY-D vaccine administered 8 weeks apart
Trial: 33134951
Drug: Nebulized DAS181
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized DAS181 (4.5 mg) twice a day for 10 days
Trial: 33135120
Drug: Daily self-reported
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-reported activity in patients with BD
Trial: 33135120
Drug: Daily self-reported
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-reported activity in unaffected relatives (UR)
Trial: 33136058
Drug: Injectable Amoxicillin
RxNorm normalized name: amoxicillin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Amoxicillin every 12 hours plus once-daily injectable Gentamicin
Trial: 33136058
Drug: Injectable Ampicillin
RxNorm normalized name: ampicillin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Ampicillin every 6 hours plus once-daily injectable Gentamicin
Trial: 33136058
Drug: Injectable Amoxicillin
RxNorm normalized name: amoxicillin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Amoxicillin plus Gentamicin
Trial: 33137019
Drug: PRESERFLO MicroShunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRESERFLO MicroShunt implantation with adjunctive mitomycin C (0.4 mg/mL)